Bayer’s Strategic Pivot: Digital Kudos and Biofuel Alliance Vie with Glyphosate Shadow

Bayer shares gain 2-3% after digital culture study top rating and BP camelina biofuel deal, but glyphosate litigation shift to California court and year-to-date losses keep old risks alive.

Bayer is trying to rewrite its narrative. No longer content to be seen as a legacy agchem giant saddled with litigation, the group is casting itself as a platform spanning health, nutrition, and energy. Thursday’s trading captured that tension: shares jumped 2.35% to €35.33 according to one reading, while another report put the gain at 3.07% to €35.58. The move briefly lifted the stock to the top of the DAX, yet the year-to-date slide — 6.43% or roughly 7%, depending on the data set — and a 28.7% to 29% gap from the 52-week high of €49.93 remind investors that the old risks remain very much alive.

Digitalization study puts Bayer at the head of the class

A new report from Instinctif Partners awards Bayer a rare accolade. The consultancy’s “Digital Culture Study” gave the company four out of five stars, tying with Merck for the best score in the chemicals and pharmaceuticals sector. The finding is notable because the industry as a whole is considered weak on digital adoption. Analysts see the rating as evidence that Bayer’s operational overhaul is gaining traction — a fundamental argument that offered support to the share price on Thursday.

BP alliance turns camelina into a strategic lever

Away from the courtroom, Bayer has pulled off its most interesting strategic move in months. The company and BP announced a long-term alliance to commercialise the oilseed crop camelina under the brand newgold™ as a feedstock for biofuels. Bayer contributes seed technology and farmer access; BP brings refinery expertise. Camelina grows as a cover crop on less intensively used land, opening a route into renewable diesel and sustainable aviation fuel.

For Bayer, the deal transforms its seeds business from a simple input supplier into a participant in a new value chain. It positions the group at the intersection of agriculture and energy — far more than a sustainability project. The market is not yet treating it as a game-changer: the stock’s relative strength index stands at 38.6 (or 40.2 in another calculation), well below euphoric levels, and volatility of 38.4% signals that traders still treat Bayer as an event-driven name rather than a reliable quality holding.

New judge, familiar legal headache

Even as the digital study and the BP alliance burnish the operational story, the legal front produces fresh uncertainty. Responsibility for the key glyphosate settlement proceedings has been shifted from a Missouri court to a federal court in California, with a new judge taking over. Observers note that California courts have tended to rule against the company in the past, leaving the stock exposed to fresh bouts of volatility at any moment.

Pharma pipeline gets a boost — but no breakthrough yet

Bayer is also trying to shift the capital-markets debate from the past to the future on the pharmaceutical side. The company announced it has fully acquired Perfuse Therapeutics, adding the eye-disease candidate PER-001, aimed at glaucoma and diabetic retinopathy. The deal is subject to regulatory approvals.

Meanwhile, at the ASCO congress, Bayer presented head-to-head data comparing NUBEQA® with enzalutamide in prostate cancer. The results were not a home run, but they signal the company’s determination to move the conversation toward its pipeline. Whether that narrative gains traction depends on concrete milestones — the BP alliance must prove it can move from pilot to profit, and the pharma candidates need to deliver clear data.

Chart watch: the 200-day moving average comes into view

Technically, the next threshold is clear. The stock traded just 1.2% below its 200-day moving average of €35.76 on Thursday. A clean break above that level would send a positive signal to chart-watchers. But with a new judge in California and a legal sword hanging over the stock, operational progress alone may not be enough to lift Bayer out of its entrenched discount. The coming weeks will test whether the company’s new story — digital stars, biofuel partnerships, and pipeline steps — can finally outweigh the glyphosate anchor.